HBW-012462

Part 1: Dose Escalation and PK Expansion Phase (Phase I) (1) Primary Objectives 1) To evaluate the safety and tolerability of HBW-012462 in patients with locally advanced or metastatic lung cancer and other solid tumors carrying KRAS mutations, to explore the MTD of HBW-012462, and to recommend a reasonable dosing regimen (RP2D) for the Phase II clinical trial. (2) Secondary Objectives 1) To evaluate the PK characteristics of HBW-012462 in patients with locally advanced or metastatic lung cancer and other solid tumors carrying KRAS mutations; 2) To evaluate the preliminary antitumor efficacy of HBW-012462 in patients with locally advanced or metastatic lung cancer and other solid tumors carrying KRAS mutations. Part 2: Dose Expansion Phase (Phase II) (1) Primary Objectives 1) To evaluate the objective response rate (ORR) of HBW-012462 in patients with locally advanced or metastatic lung cancer carrying KRAS mutations. (2) Secondary objectives: 1) To evaluate other efficacy endpoints of HBW-012462 in patients with locally advanced or metastatic lung cancer carrying KRAS mutations; 2) To evaluate the safety of HBW-012462 in patients with locally advanced or metastatic lung cancer carrying KRAS mutations; 3) To evaluate the pharmacokinetic characteristics of HBW-012462 in patients with locally advanced or metastatic lung cancer carrying KRAS mutations.